

Traverse, Wednesday, August 31, 2022, 07.30-08.30, Hall Kyoto

Classical Homocystinuria and Development of a New Enzyme Replacement Therapy

Welcome and Introduction

Can Ficicioglu, Philadelphia, United States - Andrew Morris, Manchester, United Kingdom

Overview of Classical HCU

Andrew Morris, Manchester, United Kingdom

Current Management of Classical HCU

Andrew Morris, Manchester, United Kingdom

Case Study: Patient Journey and Experience with Classical HCU

Can Ficicioglu, Philadelphia, United States

COMPOSE Phase 1/2 Trial: Overview of Interim Data on Pegtibatinase

Can Ficicioglu, Philadelphia, United States

Your Questions Answered

Can Ficicioglu, Philadelphia, United States - Andrew Morris, Manchester, United Kingdom

sponsored by

